# Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy

> **NCT03826589** · NA · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 23 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT03826589
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03826589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03826589, "Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03826589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*